TNF and neoplasm: In the treatment of malignant mesothelioma, intraperitoneal administration of either MSCs alone or MSCs-TRAIL decreased the peritoneal inflammation by reducing levels of inflammatory cytokines IL-1α, CCL2 and TNF-α [22], indicating the inflammatory downregulation by MSCs in tumor microenvironment may also be applicable to the treatment of ovarian cancer.